One of the important features of the Fc-Fusion Proteins in vivo is that it can prolong the plasma half-life of the desired protein. This feature of the Fc-Fusion Protein improves the therapeutic efficacy of the biological drugs. Fc-Fusion Proteins are now routinely used in the non-clinical applications like immunohistochemistry, protein arrays, and flow cytometry.In these applications, the FC region is stable and folds independently to which other different types of proteins can get attached and remain functional.
On the basis of Application
- In vitro
- Immunohistochemistry
- Flow Cytometry
- Binding assays
- Microarray technologies
- In vivo
- Bio-therapeutic Drugs
On the basis of End-Users
- Hospitals and ASCs
- Ophthalmic or oculoplastic clinics
On the basis of Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
There are many Fc-fusion proteins in clinical trials, and many are there at different stages of pre-clinical development.Fc-Fusion proteins and monoclonal antibodies collectively account for a total of 43% among the all therapeutic proteins market. Many Fc-Fusion proteins are still in pipeline which indicates that the market of Fc-Fusion Proteins is likely to rise in the forecast period 2016-2024.
From studies and global sales, the most successful Fc-fusion protein is Etanercept, which exceeded the utmost successful therapeutic antibody Bevacizumab. The market for Fc-fusion protein market is analogous to the biologics, pharmaceuticals and biotechnology market.
Pre-Book Right Now for Exclusive Analyst Support @ https://www.persistencemarketresearch.com/checkout/16414
Astellas Pharma US, Regeneron, Amgen, Ligand Pharmaceuticals, Bristol-Myers Squibb, Viventia and Genzyme.